Matinas BioPharma Holdings, Inc.
AMEX:MTNB
0.2346 (USD) • At close November 17, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1.096 | 3.188 | 0.033 | 0.158 | 0.09 | 0.12 | 0.15 | 0 | 0.194 | 0 | 0 | 0 |
| Cost of Revenue
| 0.941 | 16.678 | 0.781 | 14.359 | 11.235 | 6.787 | 9.01 | 0.053 | 5.292 | 5.176 | 0 | 0 |
| Gross Profit
| 0.155 | -13.49 | -0.748 | -14.201 | -11.145 | -6.668 | -8.861 | -0.053 | -5.098 | -5.176 | 0 | 0 |
| Gross Profit Ratio
| 0.141 | -4.231 | -22.445 | -89.688 | -123.828 | -55.68 | -59.196 | 0 | -26.21 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 14.489 | 16.678 | 14.583 | 14.359 | 11.235 | 6.787 | 9.01 | 3.948 | 5.292 | 5.176 | 1.761 | 0.079 |
| General & Administrative Expenses
| 10.373 | 11.1 | 10.185 | 10.006 | 7.776 | 7.979 | 7.642 | 4.309 | 4.814 | 5.289 | 1.951 | 0.037 |
| Selling & Marketing Expenses
| -0.941 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 9.432 | 11.1 | 10.185 | 10.006 | 7.776 | 7.979 | 7.642 | 4.309 | 4.814 | 5.289 | 1.951 | 0.037 |
| Other Expenses
| 0.34 | -16.678 | 0.123 | 0.686 | 0.541 | 0.057 | 0.022 | -0.017 | 0.02 | -0.025 | -0.001 | 0 |
| Operating Expenses
| 23.921 | 11.1 | 24.768 | 24.365 | 19.011 | 14.766 | 16.652 | 8.257 | 10.106 | 10.465 | 3.712 | 0.116 |
| Operating Income
| -23.766 | -24.59 | -24.735 | -24.207 | -18.921 | -14.647 | -16.502 | -8.257 | -9.911 | -10.465 | -3.712 | -0.116 |
| Operating Income Ratio
| -21.684 | -7.713 | -742.05 | -152.884 | -210.233 | -122.309 | -110.246 | 0 | -50.96 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.824 | 3.593 | 1.451 | 1.76 | 1.548 | 0.057 | 0.659 | 0.658 | 0.776 | 0.244 | -0.001 | 0 |
| Income Before Tax
| -22.942 | -20.997 | -23.283 | -22.447 | -17.373 | -14.59 | -15.843 | -7.599 | -9.135 | -10.221 | -3.713 | -0.116 |
| Income Before Tax Ratio
| -20.932 | -6.586 | -698.509 | -141.77 | -193.033 | -121.837 | -105.844 | 0 | -46.97 | 0 | 0 | 0 |
| Income Tax Expense
| 0.773 | -7.982 | -2.11 | -1.848 | -1.788 | -0.507 | -0.357 | -0.675 | -0.756 | -0.269 | 0 | 0 |
| Net Income
| -22.942 | -13.015 | -21.173 | -20.599 | -15.585 | -14.083 | -15.486 | -7.599 | -9.135 | -10.221 | -3.713 | -0.116 |
| Net Income Ratio
| -20.932 | -4.082 | -635.21 | -130.099 | -173.169 | -117.604 | -103.459 | 0 | -46.97 | 0 | 0 | 0 |
| EPS
| -0.11 | -0.06 | -0.1 | -0.1 | -0.11 | -0.14 | -0.17 | -0.13 | -0.18 | -0.32 | -0.12 | -0.012 |
| EPS Diluted
| -0.11 | -0.06 | -0.1 | -0.1 | -0.11 | -0.14 | -0.17 | -0.13 | -0.18 | -0.32 | -0.12 | -0.012 |
| EBITDA
| -22.825 | -28.081 | -26.063 | -25.28 | -19.928 | -14.428 | -17.039 | -8.879 | -10.624 | -10.693 | -3.711 | 0 |
| EBITDA Ratio
| -20.826 | -8.808 | -781.905 | -159.662 | -221.422 | -120.486 | -113.829 | 0 | -54.626 | 0 | 0 | 0 |